First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Zymeworks Inc. (ZYME): the developments shaping its investment case

    Follow the evidence affecting Zymeworks Inc.'s financing assumptions, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Zymeworks Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-10
    Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger
    Channel: Direct impact on merger completion probability and potential legal costs.
    Bearish· 1-3m
    2026-08-21
    Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR
    Channel: Direct acquisition of a public company, impacting financial structure, pipeline, and operational integration.
    mixed· 3-12m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-06-29waccBullishHigher cost-of-debt tranche lifts blended WACC.
    2026-06-29interest_expenseBullishHigh-yield coupon materially raises interest burden.
    2026-06-29net_debtBullishSub-IG debt raise increases leverage and net debt.
    2026-06-29share_countBullishStock component of consideration dilutes existing acquirer holders.
    2026-06-29net_debtBullishCash component of consideration is typically debt-funded, raising net debt.
    2026-06-29revenueBullishAcquisition adds target revenue to acquirer P&L on close.

    Event impact log

    2 events mapped to ZYME since 2026-08-21. Evidence through 2026-09-10.

    DateEventChannelDirectionHorizonImpact
    2026-09-10Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. mergerDirect impact on merger completion probability and potential legal costs.Bearish1-3m0.70
    2026-08-21Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVRDirect acquisition of a public company, impacting financial structure, pipeline, and operational integration.mixed3-12m0.70

    Continue this research

    Build your Zymeworks Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the ZYME entity page →

    Research Zymeworks Inc. · $399/mo